Although CART-19 treatment targeting CD19 achieves a 70% response rate in patients with B cell acute lymphoblastic leukemia, tumors can also evade treatment via generating CD19 isoforms lacking exon 2 (Sotillo et al., 2015). Here, CD19 is linked to B-cell acute lymphoblastic leukemia.